64 Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours After Injection.
Autor: | Loft M; Department of Clinical Physiology, Nuclear Medicine, and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark., Carlsen EA; Department of Clinical Physiology, Nuclear Medicine, and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark., Johnbeck CB; Department of Clinical Physiology, Nuclear Medicine, and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark., Johannesen HH; Department of Clinical Physiology, Nuclear Medicine, and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark., Binderup T; Department of Clinical Physiology, Nuclear Medicine, and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark., Pfeifer A; Department of Clinical Physiology, Nuclear Medicine, and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark., Mortensen J; Department of Clinical Physiology, Nuclear Medicine, and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark., Oturai P; Department of Clinical Physiology, Nuclear Medicine, and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark., Loft A; Department of Clinical Physiology, Nuclear Medicine, and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark., Berthelsen AK; Department of Clinical Physiology, Nuclear Medicine, and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark., Langer SW; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark.; Department of Oncology, Rigshospitalet, Copenhagen, Denmark; and., Knigge U; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark.; Departments of Clinical Endocrinology and Surgical Gastroenterology, Rigshospitalet, Copenhagen, Denmark., Kjaer A; Department of Clinical Physiology, Nuclear Medicine, and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark akjaer@sund.ku.dk.; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark. |
---|---|
Jazyk: | angličtina |
Zdroj: | Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2021 Jan; Vol. 62 (1), pp. 73-80. Date of Electronic Publication: 2020 May 22. |
DOI: | 10.2967/jnumed.120.244509 |
Abstrakt: | 64 Cu-DOTATATE PET/CT imaging 1 h after injection is excellent for lesion detection in patients with neuroendocrine neoplasms (NENs). We hypothesized that the imaging time window can be extended up to 3 h after injection without significant differences in the number of lesions detected. Methods: From a prospective study, we compared, on a head-to-head basis, sets of 64 Cu-DOTATATE PET/CT images from 35 patients with NENs scanned 1 and 3 h after injection of 200 MBq of 64 Cu-DOTATATE. The number of lesions on both PET scans was counted and grouped according to organs or regions and compared with negative binomial regression. Discordant lesions (visible on only the 1-h images or only the 3-h 64 Cu-DOTATATE PET images) were considered true if found on simultaneous CT or later MR, CT, or somatostatin receptor imaging. We measured lesion SUV (© 2021 by the Society of Nuclear Medicine and Molecular Imaging.) |
Databáze: | MEDLINE |
Externí odkaz: |